NCT05112016|Recruiting
Long-term Cohort Study of Mesorectal Excision for Rectal Cancer
TME-KSW
Loading search results
TME-KSW
Sponsor study identifier
observational
250
1 country
1
Study Start
January 1, 2007
Actual (reported)Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The aim of this cohort study is to record, evaluate and compare the surgical, oncological as well as the functional outcome and Quality of life after mesorectal excision for rectal cancer
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2007
Actual (reported)September 6, 2021
Actual (reported)November 8, 2021
Actual (reported)December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Perioperative mortality
Reporting perioperative mortality with Clavien-Dindo \& Comprehensive Complications Index
90 days
Age
Age (years)
10 years
Body mass index
BM (kg/m2)
10 years
Gender
Sex (male, female)
10 years
ASA score
American Society of Anesthesiologists score (I to V)
Perioperative treatment
10 years
Surgery time
day of surgery
Length of hospital stay
90 days
Readmission rate
90 days
Costs
10 years
Patients with rectal cancer treated by TME (laparoscopic TME, transanal TME, robotic TME, open TME)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with rectal cancer who benefit from surgical resection
Kantonsspital Winterthur
Winterthur, Canton of Zurich, 8401, Switzerland
Michel Adamina, Prof/MD/MSc
Kantonsspital Winterthur KSW
Kantonsspital Winterthur
CONTACT
First Submitted
September 6, 2021
First Posted
November 8, 2021
Study Start
January 1, 2007
Actual (reported)Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects
10 years
Date of surgery
date of surgery (day-month-year)
day of surgery
Tumor localisation
Description of tumor localisation
10 years
Comorbidities
Charlson index
day of surgery
Perioperative complications
Reporting and grading of postoperative surgical complications (according to Dindo-Clavien classification and/or comprehensive complications index)
90 days
Histological results
Histological staging and grading of the specimen by a pathologist
30 days
Quality of life, including functional and symptom scales, incontinence scores, sexual function
taTME survey (validated english, german, french versions); from 0 (worst) to 100 (best)
10 years
Contact the study team to confirm eligibility.
Study Completion
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
November 8, 2021
Record last verified: 2021-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: